Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations.

ABSTRACT: Drug resistance, de novo and acquired, pervades cellular signaling networks (SNs) from one signaling motif to another as a result of cancer progression and/or drug intervention. This resistance is one of the key determinants of efficacy in targeted anti-cancer drug therapy. Although poorly understood, drug resistance is already being addressed in combination therapy by selecting drug targets where SN sensitivity increases due to combination components or as a result of de novo or acquired mutations. Additionally, successive drug combinations have shown low resistance potential. To promote a rational, systematic development of combination therapies, it is necessary to establish the underlying mechanisms that drive the advantages of combination therapies, and design methods to determine drug

SUBMITTER: Goltsov A 

PROVIDER: S-EPMC3914444 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature